Diffuse Lung Disease
-
TETON-1 treatment effects offer hope for patients with idiopathic pulmonary fibrosis
Christopher King, MD, FCCP, and Steven D. Nathan, MD, FCCP, discuss the clinical implications of inhaled treprostinil, including the medication’s potential use in future combination treatment strategies.
-
Honoring a legacy, empowering the future
The John R. Addrizzo, MD, FCCP, Endowed Research Grant in Sarcoidosis, a transformative and permanent fund dedicated to advancing research in sarcoidosis, is not only a tribute to a beloved husband, father, grandfather, and physician but also a beacon for progress and discovery.
-
Phase 3 TETON trials demonstrate positive results for inhaled treprostinil for IPF
Steven D. Nathan, MD, FCCP, said the evidence shows the drug is effective for treating pulmonary hypertension and may slow or prevent fibrosis progression.
-
Data show oral nalbuphine significantly reduces chronic cough in idiopathic pulmonary fibrosis
Experts discuss the promising results—particularly surrounding patient-reported outcomes in this population—and the need for long-term safety data.
-
Study links nocturnal GERD, undiagnosed OSA to worse outcomes in IPF
Researchers said the findings support evaluation of sleep‑related comorbidities to identify potentially modifiable contributors to symptoms and physiologic impairment.
-
Optimal synergy: Coupling smart wearable devices, sensors with AI algorithms
Coupling noninvasive wearable devices with AI-enabled data analytics helps to address two key challenges: health care access and improvement of patient-centric care.
-
Phase 3 IMPALA-2 clinical trial shows inhaled molgramostim promising for autoimmune pulmonary alveolar proteinosis
An ongoing 96-week, open-label period of the trial is designed to shed light on the drug’s long-term safety and efficacy.
-
Imaging panel discusses pace, direction of practical AI applications
Amit Gupta, MD, MRMD, CIIP, spoke about the growing application of AI imagery in early-stage lung cancer detection.
-
Sarcoidosis experts review decisions from diagnosis to transplant
Hakim Azfar Ali, MD, MPH, FCCP, discussed indications and timing for lung transplantation referral in patients with sarcoidosis.
-
Radiologists, pulmonologists to discuss identification of interstitial lung abnormalities
Joe Mammarappallil, MD, PhD, will chair a Monday afternoon session on the recognition and risk stratification of ILAs, including how to differentiate imaging red herrings from findings that point toward progressive fibrosis.
